Relmada Therapeutics Inc

Relmada Therapeutics Inc

RLMD - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$449.08M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Relmada Therapeutics IncRelmada Therapeutics Inc-5.7--34%--
$0.09

Current Fair Value

97.9% downside

Overvalued by 97.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$449.08 Million
Enterprise Value$443.36 Million
Earnings per Share$-1.45
Beta0.45
Outstanding Shares112,437,710

Return

Return on Equity-33.91%ROE
Return on Assets-32.00%
Return on Invested Capital-33.44%

Valuation & Multiples

P/E Ratio-5.69P/E Ratio
PEG-15.23PEG
Price to Sales-Price to Sales
Price to Book Ratio4.21Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-6.71
Enterprise Value to Net Income-7
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$0.12
Est. -$0.14
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 18, 2027
EPS Estimate
-$0.16
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-▼ 100.00%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %3.84%▼ 86.25%
Total Invested$16.27M▼ 97.68%
Investors Holding26▼ 105.00%

About Relmada Therapeutics Inc

14 employees
CEO: Sergio Traversa

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference ...

Relmada Therapeutics Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in Relmada Therapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 4 open-market insider purchases for Relmada Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.